Back to Search
Start Over
CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.
- Source :
- Advanced Biosystems; Nov2018, Vol. 2 Issue 11, pN.PAG-N.PAG, 1p
- Publication Year :
- 2018
-
Abstract
- Molecularly, breast cancer represents a highly heterogenous family of neoplastic disorders, with substantial interpatient variations regarding genetic mutations, cell composition, transcriptional profiles, and treatment response. Consequently, there is an increasing demand for alternative diagnostic approaches aimed at the molecular annotation of the disease on a patient‐by‐patient basis and the design of more personalized treatments. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated (Cas) technology enables the development of such novel approaches. For instance, in diagnostics, the use of the RNA‐specific C2c2 system allows ultrasensitive nucleic acid detection and could be used to characterize the mutational repertoire and transcriptional breast cancer signatures. In disease modeling, CRISPR/Cas9 technology can be applied to selectively engineer oncogenes and tumor‐suppressor genes involved in disease pathogenesis. In treatment, CRISPR/Cas9 can be used to develop gene‐therapy, while its catalytically‐dead variant (dCas9) can be applied to reprogram the epigenetic landscape of malignant cells. As immunotherapy becomes increasingly prominent in cancer treatment, CRISPR/Cas9 can engineer the immune cells to redirect them against cancer cells and potentiate antitumor immune responses. In this review, CRISPR strategies for the advancement of breast cancer diagnostics, modeling, and treatment are highlighted, culminating in a perspective on developing a precision medicine‐based approach against breast cancer. The limitations of current breast cancer diagnostics, modeling, and treatment methods are recounted followed by approaches in which clustered regularly interspaced short palindromic repeats (CRISPR) variants can be exploited for more precise outcomes. The review concludes by analyzing the present barriers for CRISPR delivery and translation, highlighting the engineering innovations to overcome them. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23667478
- Volume :
- 2
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Advanced Biosystems
- Publication Type :
- Academic Journal
- Accession number :
- 132916080
- Full Text :
- https://doi.org/10.1002/adbi.201800132